Heritage Distilling Co. Announces Sell Out of First Run of 80th Anniversary of the Battle of Iwo Jima Bourbon; Announces Passing $200,000 Raised for Military Charities
Heritage to Commence Second Run of Salute Series 'Battle of Iwo Jima: 80th Anniversary Edition' Bourbon in Response to High Demand
Heritage Distilling Company
GIG HARBOR, Wash., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Heritage Distilling Company, Inc. ("HDC" or "Heritage" or the 'Company') (Nasdaq: CASK), a leading craft distiller of innovative premium brands, announced that in response to its initial release of 2,200 bottles of its Salute Series: 'Battle of Iwo Jima: 80th Anniversary Edition' in partnership with the Marine Raider Foundation (MRF), it will be releasing one final batch of 2,000 bottles commemorating the battle, which took place over five weeks between February 19, 1944 and March 26, 1944.
'The response to our initial release of 2,200 bottles of this 80th Anniversary bourbon commemorating the Battle of Iwo Jima was greater than we anticipated, selling out in a matter of a few weeks. Given the response and request for more, we've elected to complete one final run of bottles to service the expressed requests for our customers,' said Sara Kellerman, military veteran, co-founder and vice president of Heritage Distilling Company's Salute Series line of spirits.
In just the first three weeks of sales from the initial bottling run, the product generated nearly $200,000 in retail sales value and nearly $20,000 in donations for the Marine Raider Foundation to support their mission of addressing unmet needs, building resiliency and preserving the legacy of Raiders, past and present.
'This latest release under our Salute Series line of products shows we are able to create compelling products that resonate with active duty and retired military and first responder communities,' said Justin Stiefel, CEO and co-founder of Heritage Distilling. 'The margins on this product line are industry leading, led by our direct-to-consumer route to market, followed by the increasing demand we are seeing from the wholesale distribution channel as word of the product grows. This approach allows us to direct a significant portion of the sales to carefully vetted non-profit charities who do great work every day to support our active duty and retired military and first responders and their families.'
The Salute Series is the first-of-its-kind spirits line branded and marketed for the people on the front lines, those who have retired from previous service and their families. The Salute Series brand stands as its own full line of premium whiskies and bourbons in the broader HDC portfolio, and is the fastest growing piece of the Company's volume and revenue. Each label is geared towards specific operators in the military and first responder community, allowing those who have been on the ground, or worn specific badges or insignias, to claim as their own the product that speaks the most to them and tells their story. Each bottle sold raises money for non-profit charities supporting the military and first responder communities. Since the launch of the Salute Series, more than $200,000 has been raised for these worthy charities under HDC's program.
The latest 80th Anniversary of Iwo Jima bottle hints at the iconic Pulitzer Prize-winning image of the American flag on Mount Suribachi, a symbol of American resilience and determination, while focusing on the intensity of the warriors who were on the ground executing the mission.
Exclusive features of the 'Iwo Jima: 80th Anniversary Edition' include:
Bottled at 'Howitzer strength,' this 105-proof straight bourbon whiskey has been aged for 5 years, offering a bold and robust flavor profile.
The label features exclusive art by Michael Solovey, whose work helps bring the Salute Series to life. The design reflects the black volcanic ash that covers Iwo Jima, tying the whiskey to the battle's historical context.
Customers who purchase two bottles will receive a frameable lithograph by Michael Solovey titled 'GUNG HO,' inspired by the iconic flag-raising and designed to honor the Marine Corps' enduring spirit.
For more information and to purchase Heritage's award-winning spirits, visit heritagedistilling.com.
About Heritage Distilling Company, Inc.Heritage is among the premier independent craft distilleries in the United States offering a variety of whiskeys, vodkas, gins, rums and ready-to-drink canned cocktails. Heritage has been North America's most awarded craft distillery by the American Distilling Institute for ten consecutive years out of the more than 2,600 craft producers. Beyond this remarkable achievement, Heritage has also garnered numerous Best of Class, Double Gold, and Gold medals at esteemed national and international spirits competitions. As one of the largest craft spirits producers on the West Coast by revenue, the company is expanding its presence nationwide through a diverse range of sales channels, including wholesale, on-premises venues, e-commerce and the innovative Tribal Beverage Network (TBN). The TBN initiative, a groundbreaking collaboration with Native American tribes, focuses on developing Heritage-branded distilleries, unique tribal brands and tasting rooms tailored to tribal communities. By serving patrons of tribal casinos and entertainment venues, the TBN creates meaningful economic and social benefits for participating tribes, while providing an additional avenue for tribes to exercise and strengthen their sovereignty. This unique partnership reflects Heritage's commitment to innovation, community engagement and sustainable growth.
Forward-Looking StatementsThis press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding anticipated results or benefits anticipated from Heritage's new product launch and the implications that may come from it.
Any forward-looking statements in this press release are based on Heritage's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks of expanding sales and revenue due to the introduction of new products or the announcement of new partnerships that would be expected to result therefrom. These and other risks concerning Heritage's programs and operations are described in additional detail in its registration statement on Form S-1, and its quarterly 10-Q filings, which are on file with the SEC. Heritage explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contacts:
Investors
Media
Scott Eckstein
Francesca DeMauro
heritage@ksca.com
heritage@ksca.com
(212) 896 1210
(917) 880 9771
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8e8f0a65-eced-4ef8-bbbb-9d1272253527.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM)
Insmed Incorporated (NASDAQ:INSM) is among the 13 Biotech Stocks with Huge Upside Potential. Kelly Shi of Jefferies has given Insmed Incorporated (NASDAQ:INSM) a buy recommendation, stating that she is confident in the TPIP treatment's impending Phase 2 data for pulmonary arterial hypertension. A biopharmaceutical research team taking notes in front of a laboratory's microscope. Shi anticipates a substantial decrease in pulmonary vascular resistance, the main outcome of the trial, of 20%, which is regarded as a definite success. If the results are encouraging, TPIP may replace Tyvaso, the current standard treatment. On June 4, Wells Fargo reaffirmed its Buy recommendation, with a price objective of $107. Shi points out that TPIP's once-daily dosage is a significant benefit over Tyvaso's four-times-daily schedule, which could increase adherence and make it more appealing to patients as well as physicians. The efficacy potential of TPIP is supported by interim study results that show additional advantages in six-minute walk distance (6MWD). Shi expects significant market penetration in light of these considerations, which could lead to an increase in Insmed Incorporated (NASDAQ:INSM)'s valuation. Both analysts highlight that if future trial results live up to predictions, TPIP has the potential to completely change the way that PAHs are treated. Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical firm that improves the lives of individuals suffering from serious and rare diseases. While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
US Appeals Court Confirms Patent Validity of Acadia's Parkinson's Medication
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is among the 13 Biotech Stocks with Huge Upside Potential. It declared that the U.S. Court of Appeals maintained the legality of its composition of matter patent for the medication Nuplazid, which treats psychosis in Parkinson's disease. A research scientist looking through a microscope in a lab, symbolizing the biopharmaceutical company's innovative approach to medical treatments. The verdict supports ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in its legal struggle with India-based MSN Laboratories and upholds a December 2023 ruling by the U.S. District Court of Delaware. A later patent claim with the same priority date cannot be declared invalid by the court. According to CEO Catherine Owen Adams, Nuplazid's patent protection has been extended to 2030. The 34 mg capsule is also protected by a separate formulation patent that runs through 2038. The U.S. FDA authorized Nuplazid in 2016 to treat delusions and hallucinations linked to psychosis in Parkinson's disease. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)'s legal stance in a different action against Aurobindo Pharma was further strengthened by the latest decision. When taken as a whole, these results solidify the company's portfolio of intellectual property in the face of generic competition, guaranteeing prolonged market exclusivity for its flagship neurological medication. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical firm that specializes in the creation and marketing of medications that treat uncommon diseases and disorders of the central nervous system. While we acknowledge the potential of ACAD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26
Ascendis Pharma A/S (NASDAQ:ASND) is among the 13 Biotech Stocks with Huge Upside Potential. It reported interim Week 26 data from its Phase 2 COACH Trial, confirming that combining TransCon hGH (lonapegsomatropin) with TransCon CNP (navepegritide) raised annualized growth velocity (AGV) and height Z-scores in children with achondroplasia. A close-up view of a hand manipulating a syringe while delivering TransCon CNP into a tumor. A mean AGV of 9.14 cm/year and a +0.53 Z-score rise were attained by treatment-naïve youngsters (N=12). Children (N=9) treated with TransCon CNP in the past achieved an AGV of 8.25 cm/year with a +0.44 Z-score improvement. The majority of side effects were modest, and safety remained consistent with monotherapies. The COACH Trial is the first to assess this combination in kids between the ages of two and eleven. While TransCon CNP is undergoing FDA priority review, TransCon hGH is approved as SKYTROFA® for juvenile growth hormone insufficiency. The treatment focuses on the FGFR3-CNP signaling imbalance that is at the heart of achondroplasia, a disorder that affects more than 250,000 people worldwide. It is anticipated that the results of week 52 and a scheduled Phase 3 trial in Q4 2025 will further clarify efficacy and long-term benefits. The biopharmaceutical business Ascendis Pharma A/S (NASDAQ:ASND) uses its TransCon technology platform to significantly improve patient outcomes. While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None.